Abstract 5015
Background
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in china. Because the disease often has no symptoms in the early stages, it is usually detected at a more advanced stage that is more challenging to treat. The inter-communication between esophageal squamous cell carcinoma and its surrounding microenvironment is essential for tumor progression and metastasis. Exosome plays a key role in information delivery between primary lesion and pre-metastatic niche via its packed bioactive molecules. The aim of this study is to explore the effect of exosome from tumor plasma to angiogenesis in human lymphatic endothelial cells (HLEC) in vitro.
Methods
Total circulation exosomes (CEs) were extracted and purified to selectively capture EpCAM positive exosomes by magnetic-bead technique. Proteins were separated by SDS-PAGE, and protein bands were analyzed by mass spectrometry. Tube formation assay and fluorescence imaging assay were performed in vitro.
Results
The expression level of CEs in ESCC patients with lymph node metastasis were significantly higher than that in ESCC patients without metastasis and healthy control group (respectively; P < 0.001). The tumor associated exosomes could be taken by HLEC and its transferred into HLECs could to promote HLECs tube formation in vitro. In addition, the mass spectrometry was used to analysis the proteomic content in tumor associated exosomes, tumor-related proteins such as matrix-metalloproteinases, PP2A proteins and EIF proteins were identified in the exosome.
Conclusions
Exosomes released by ESCC may play important roles in the microenvironment of ESCC and provide a potential application of therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
NSFC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract